

## Summary of Changes

Effective for dates of service on or after **July 15, 2025**, the changes listed in the document below will apply to **EviCore Radiation Oncology Guidelines**. As part of the EviCore guidelines review process, these updates are focused on advancing efforts to drive clinically appropriate, safe and affordable healthcare services.

These changes will only apply to V1.0.2025 Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) Guidelines Effective **July 15, 2025**:

- Added recently approved FDA expansion of use in individuals who meet previous criteria and in whom a delay in taxane-based chemotherapy has been determined to be appropriate.
- Removed specific radiotracers from PSMA PET/CT scan.
- Updated recommended number of cycles.
- NCCN reference updated, and new reference added.